Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,445

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Rheumatoid arthritis

Open access
Smolen, Josef S., Aletaha, Daniel, Barton, Anne, Burmester, Gerd R., Emery, Paul, Firestein, Gary S., Kavanaugh, Arthur, McInnes, Iain B., Solomon, Daniel H., Strand, Vibeke, Yamamoto, Kazuhiko·2018·Nature Reviews Disease Primers
DOI 10.1038/nrdp.2018.1
Open this paper in CoChat — free account

Abstract

Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease that primarily affects the joints and is associated with autoantibodies that target various molecules including modified self-epitopes. The identification of novel autoantibodies has improved diagnostic accuracy, and newly developed classification criteria facilitate the recognition and study of the disease early in its course. New clinical assessment tools are able to better characterize disease activity states, which are correlated with progression of damage and disability, and permit improved follow-up. In addition, better understanding of the pathogenesis of RA through recognition of key cells and cytokines has led to the development of targeted disease-modifying antirheumatic drugs. Altogether, the improved understanding of the pathogenetic processes involved, rational use of established drugs and development of new drugs and reliable assessment tools have drastically altered the lives of individuals with RA over the past 2 decades. Current strategies strive for early referral, early diagnosis and early start of effective therapy aimed at remission or, at the least, low disease activity, with rapid adaptation of treatment if this target is not reached. This treat-to-target approach prevents progression of joint damage and optimizes physical functioning, work and social participation. In this Primer, we discuss the epidemiology, pathophysiology, diagnosis and management of RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrdp.2018.1

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 243

  1. Malmstrom, V., Catrina, A. I. & Klareskog, L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat. Rev. Immunol. 17, 60–75 (2017). · DOI · Paper page
  2. Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M. & Gabriel, S. E. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 62, 1576–1582 (2010). · DOI · Paper page
  3. Tobon, G. J., Youinou, P. & Saraux, A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J. Autoimmun 35, 10–14 (2010). · DOI · Paper page
  4. Malemba, J. J. et al. The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo—a population-based study. Rheumatology 51, 1644–1647 (2012). · doi:10.1093/rheumatology/kes092
  5. Peschken, C. A. & Esdaile, J. M. Rheumatic diseases in North America's indigenous peoples. Semin. Arthritis Rheum. 28, 368–391 (1999). · DOI
  6. Kawatkar, A. A., Portugal, C., Chu, L.-H. & Iyer, R. Racial/ethnic trends in incidence and prevalence of rheumatoid arthritis in a large multi-ethnic managed care population [abstract]. Arthritis Rheum. 64, S1061 (2012). · DOI
  7. MacGregor, A. J. et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43, 30–37 (2000). · DOI · Paper page
  8. Padyukov, L. et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 70, 259–265 (2011). · DOI · Paper page
  9. Gregersen, P. K., Silver, J. & Winchester, R. J. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205–1213 (1987). This is the single most important paper on the genetics of RA, after the seminal work of Peter Stastny detecting the association between RA and HLA-DR4, and explains the differences in associations found between different populations by a short amino acid sequence common to all these molecules. · DOI · Paper page
  10. Weyand, C. M., Hicok, K. C., Conn, D. L. & Goronzy, J. J. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann. Intern. Med. 117, 801–806 (1992). · DOI · Paper page
  11. Raychaudhuri, S. et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat. Genet. 41, 1313–1318 (2009). · DOI · Paper page
  12. Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44, 1336–1340 (2012). · DOI · Paper page
  13. Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330–337 (2004). · DOI · Paper page
  14. Remmers, E. F. et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357, 977–986 (2007). · DOI · Paper page
  15. Thomson, W. et al. Rheumatoid arthritis association at 6q23. Nat. Genet. 39, 1431–1433 (2007). · DOI · Paper page
  16. Barton, A. et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat. Genet. 40, 1156–1159 (2008). · DOI · Paper page
  17. Raychaudhuri, S. Recent advances in the genetics of rheumatoid arthritis. Curr. Opin. Rheumatol 22, 109–118 (2010). · DOI
  18. Karlson, E. W. et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann. Rheum. Dis. 69, 1077–1085 (2010). · DOI
  19. Viatte, S. et al. Replication of associations of genetic loci outside the HLA region with susceptibility to anti-cyclic citrullinated peptide-negative rheumatoid arthritis. Arthritis Rheumatol. 68, 1603–1613 (2016). · DOI
  20. Viatte, S. et al. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann. Rheum. Dis. 71, 1984–1990 (2012). · DOI
  21. McGovern, A. et al. Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. Genome Biol. 17, 212 (2016). · DOI
  22. Viatte, S. et al. Association between genetic variation in FOXO3 and reductions in inflammation and disease activity in inflammatory polyarthritis. Arthritis Rheumatol. 68, 2629–2636 (2016). · DOI
  23. Krabben, A., Huizinga, T. W. & Mil, A. H. Biomarkers for radiographic progression in rheumatoid arthritis. Curr. Pharm. Des. 21, 147–169 (2015). · DOI
  24. Lee, J. C. et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155, 57–69 (2013). · DOI · Paper page
  25. Oliver, J., Plant, D., Webster, A. P. & Barton, A. Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis. Biomark Med. 9, 499–512 (2015). · DOI
  26. Gomez-Cabrero, D. et al. High-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis. Genome Med. 8, 124 (2016). · DOI
  27. Liu, Y. et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. 31, 142–147 (2013). This paper describes the importance of epigenetic modifications beyond genetic factors in the pathogenesis of RA. · DOI · Paper page
  28. Meng, W. et al. DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis. Arthritis Res. Ther. 19, 71 (2017). · DOI
  29. Frank-Bertoncelj, M. et al. Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions. Nat. Commun. 8, 14852 (2017). · DOI · Paper page
  30. Ngo, S. T., Steyn, F. J. & McCombe, P. A. Gender differences in autoimmune disease. Front. Neuroendocrinol. 35, 347–369 (2014). · DOI · Paper page
  31. Crowson, C. S. et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 63, 633–639 (2011). · DOI · Paper page
  32. Alpizar-Rodriguez, D., Pluchino, N., Canny, G., Gabay, C. & Finckh, A. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology 56, 1254–1263 (2017). · DOI
  33. Alamanos, Y., Voulgari, P. V. & Drosos, A. A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin. Arthritis Rheum. 36, 182–188 (2006). · DOI · Paper page
  34. Sugiyama, D. et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 69, 70–81 (2010). · DOI · Paper page
  35. Vesperini, V. et al. Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort. Arthritis Care Res. 65, 1899–1906 (2013). · DOI
  36. Kallberg, H. et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann. Rheum. Dis. 70, 508–511 (2011). · DOI · Paper page
  37. Sokolove, J. et al. Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans. Rheumatology 55, 1969–1977 (2016). · DOI
  38. Svendsen, A. J. et al. Differentially methylated DNA regions in monozygotic twin pairs discordant for rheumatoid arthritis: an epigenome-wide study. Front. Immunol. 7, 510 (2016). · DOI
  39. Jiang, X., Alfredsson, L., Klareskog, L. & Bengtsson, C. Smokeless tobacco (moist snuff) use and the risk of developing rheumatoid arthritis: results from a case-control study. Arthritis Care Res. 66, 1582–1586 (2014). · DOI · Paper page
  40. Naranjo, A. et al. Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clin. Exp. Rheumatol. 28, 820–827 (2010).
  41. Stolt, P. et al. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann. Rheum. Dis. 64, 582–586 (2005). · DOI · Paper page
  42. Webber, M. P. et al. Nested case-control study of selected systemic autoimmune diseases in World Trade Center rescue/recovery workers. Arthritis Rheumatol. 67, 1369–1376 (2015). · DOI
  43. Too, C. L. et al. Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study. Ann. Rheum. Dis. 75, 997–1002 (2016). · DOI
  44. Kharlamova, N. et al. Antibodies to Porphyromonas gingivalis indicate interaction between oral infection, smoking, and risk genes in rheumatoid arthritis etiology. Arthritis Rheumatol. 68, 604–613 (2016). · DOI · Paper page
  45. Konig, M. F. et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci. Transl Med. 8, 369ra176 (2016). · DOI · Paper page
  46. Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2, e01202 (2013). · DOI · Paper page
  47. Pianta, A. et al. Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints. J. Clin. Invest. 127, 2946–2956 (2017). · DOI · Paper page
  48. Naciute, M. et al. Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis. J. Gen. Virol. 97, 3302–3312 (2016). · doi:10.1099/jgv.0.000621
  49. Gasque, P., Bandjee, M. C., Reyes, M. M. & Viasus, D. Chikungunya pathogenesis: from the clinics to the bench. J. Infect. Dis. 214 (Suppl. 5), S446–S448 (2016). · DOI
  50. Tan, E. M. & Smolen, J. S. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J. Exp. Med. 213, 1937–1950 (2016). · DOI
  51. Ljung, L. & Rantapaa-Dahlqvist, S. Abdominal obesity, gender and the risk of rheumatoid arthritis — a nested case-control study. Arthritis Res. Ther. 18, 277 (2016). · DOI
  52. Lu, B., Solomon, D. H., Costenbader, K. H. & Karlson, E. W. Alcohol consumption and risk of incident rheumatoid arthritis in women: a prospective study. Arthritis Rheumatol. 66, 1998–2005 (2014). · DOI
  53. Lee, Y. C. et al. Post-traumatic stress disorder and risk for incident rheumatoid arthritis. Arthritis Care Res. 68, 292–298 (2016). · DOI
  54. Camacho, E. M., Verstappen, S. M. & Symmons, D. P. Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis. Arthritis Care Res. 64, 1225–1232 (2012). · DOI
  55. Radner, H., Lesperance, T., Accortt, N. A. & Solomon, D. H. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res. 69, 1510–1518 (2017). · DOI
  56. Lopez-Mejias, R. et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. Autoimmun. Rev. 15, 1013–1030 (2016). · DOI
  57. Sparks, J. A. et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses’ Health Study. Arthritis Care Res. 68, 753–762 (2016). · DOI · Paper page
  58. Markusse, I. M. et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann. Intern. Med. 164, 523–531 (2016). · DOI
  59. Masi, A. T. Articular patterns in the early course of rheumatoid arthritis. Am. J. Med. 75, 16–26 (1983). · DOI
  60. Makrygiannakis, D. et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann. Rheum. Dis. 67, 1488–1492 (2008). · DOI · Paper page
  61. Dissick, A. et al. Association of periodontitis with rheumatoid arthritis: a pilot study. J. Periodontol. 81, 223–230 (2010). · DOI · Paper page
  62. Holers, V. M. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr. Opin. Immunol. 25, 728–735 (2013). · DOI
  63. Muller, S. & Radic, M. Citrullinated autoantigens: from diagnostic markers to pathogenetic mechanisms. Clin. Rev. Allergy Immunol. 49, 232–239 (2015). · DOI
  64. Trouw, L. A., Huizinga, T. W. & Toes, R. E. Autoimmunity in rheumatoid arthritis: different antigens — common principles. Ann. Rheum. Dis. 72 (Suppl. 2), ii132–ii136 (2013). · DOI
  65. Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580–1588 (2010). This article explains that after almost 25 years, new RA classification criteria were developed in a data-driven, consensus process; these criteria also allow classification of patients with early RA who failed to be classified with the previous criteria. · DOI · Paper page
  66. Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004). After the seminal observations of Kimmo Aho on the presence of RF and anti-keratin antibodies (which later became known as ACPAs), this paper reveals that ACPA (and RF) precedes the clinical symptoms of RA by assessing sera from blood donors. · DOI · Paper page
  67. Aletaha, D., Alasti, F. & Smolen, J. S. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res. Ther. 17, 229 (2015). · doi:10.1186/s13075-015-0736-9
  68. Laurent, L. et al. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann. Rheum. Dis. 74, 1425–1431 (2015). · DOI
  69. Sokolove, J. et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 66, 813–821 (2014). · DOI · Paper page
  70. van Beers, J. J. et al. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res. Ther. 15, R140 (2013). · DOI
  71. Deane, K. D. et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 62, 3161–3172 (2010). · DOI · Paper page
  72. de Hair, M. J. et al. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 66, 513–522 (2014). · DOI · Paper page
  73. Kraan, M. C. et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum. 41, 1481–1488 (1998). · DOI · Paper page
  74. Arend, W. P. & Firestein, G. S. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat. Rev. Rheumatol. 8, 573–586 (2012). · DOI · Paper page
  75. Steiner, G. Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools. Clin. Rev. Allergy Immunol. 32, 23–36 (2007). · DOI
  76. Kinslow, J. D. et al. Elevated IgA plasmablast levels in subjects at risk of developing rheumatoid arthritis. Arthritis Rheumatol. 68, 2372–2383 (2016). · DOI
  77. Shi, J. et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann. Rheum. Dis. 73, 780–783 (2014). · DOI · Paper page
  78. Bohler, C., Radner, H., Smolen, J. S. & Aletaha, D. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann. Rheum. Dis. 72, 241–244 (2013). · doi:10.1136/annrheumdis-2012-202297
  79. Klarenbeek, P. L. et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann. Rheum. Dis. 71, 1088–1093 (2012). · DOI · Paper page
  80. Ai, R. et al. DNA methylome signature in synoviocytes from patients with early rheumatoid arthritis compared to synoviocytes from patients with longstanding rheumatoid arthritis. Arthritis Rheumatol. 67, 1978–1980 (2015). · DOI
  81. Castor, C. W. The microscopic structure of normal human synovial tissue. Arthritis Rheum. 3, 140–151 (1960). · doi:10.1002/art.1780030205
  82. Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233, 233–255 (2010). · DOI · Paper page
  83. Stanczyk, J. et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 58, 1001–1009 (2008). · DOI · Paper page
  84. Philippe, L. et al. MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Ann. Rheum. Dis. 72, 1071–1079 (2013). · DOI
  85. Lefevre, S. et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. Med. 15, 1414–1420 (2009). · DOI · Paper page
  86. Ziff, M. Relation of cellular infiltration of rheumatoid synovial membrane to its immune response. Arthritis Rheum. 17, 313–319 (1974). · doi:10.1002/art.1780170317
  87. Randen, I. et al. Clonally related IgM rheumatoid factors undergo affinity maturation in the rheumatoid synovial tissue. J. Immunol. 148, 3296–3301 (1992). · DOI
  88. Catrina, A. I., Ytterberg, A. J., Reynisdottir, G., Malmstrom, V. & Klareskog, L. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 645–653 (2014). · DOI · Paper page
  89. Orr, C. et al. Synovial tissue research: a state-of-the-art review. Nat. Rev. Rheumatol 13, 463–475 (2017). · DOI · Paper page
  90. Kiener, H. P. et al. Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum. 60, 1305–1310 (2009). · DOI
  91. Keyszer, G. et al. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. Arthritis Rheum. 41, 1378–1387 (1998). · doi:10.1002/1529-0131(199808)41:8<1378::aid-art6>3.0.co;2-j
  92. Bottini, N. & Firestein, G. S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 9, 24–33 (2013). · DOI · Paper page
  93. Muller-Ladner, U. et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol. 149, 1607–1615 (1996).
  94. Tak, P. P., Zvaifler, N. J., Green, D. R. & Firestein, G. S. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol. Today 21, 78–82 (2000). · DOI · Paper page
  95. Ai, R. et al. Joint-specific DNA methylation and transcriptome signatures in rheumatoid arthritis identify distinct pathogenic processes. Nat. Commun. 7, 11849 (2016). · DOI
  96. Redlich, K. & Smolen, J. S. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat. Rev. Drug Discov. 11, 234–250 (2012). · DOI · Paper page
  97. Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791–1802 (2012). · DOI · Paper page
  98. Krishnamurthy, A. et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann. Rheum. Dis. 75, 721–729 (2016). · DOI · Paper page
  99. Hayer, S. et al. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum. 56, 79–88 (2007). · DOI
  100. Nakano, S. et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis. Rheumatology 54, 1498–1506 (2015). · doi:10.1093/rheumatology/keu528
  101. Behrens, F. et al. MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann. Rheum. Dis. 74, 1058–1064 (2015). · DOI
  102. Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023–2038 (2016). · DOI · Paper page
  103. Genovese, M. C. et al. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med. 374, 1243–1252 (2016). · DOI · Paper page
  104. Boyle, D. L. et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann. Rheum. Dis. 74, 1311–1316 (2015). · DOI · Paper page
  105. Genovese, M. C. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60, 317–320 (2009). · DOI · Paper page
  106. Genovese, M. C. et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-alpha antagonist. J. Rheumatol. 41, 2120–2128 (2014). · DOI
  107. Firestein, G. S. The disease formerly known as rheumatoid arthritis. Arthritis Res. Ther. 16, 114 (2014). · DOI
  108. Smolen, J. S. et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 38, 38–43 (1995). · DOI · Paper page
  109. Koduri, G. et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology 49, 1483–1489 (2010). · DOI · Paper page
  110. Bongartz, T. et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 62, 1583–1591 (2010). · DOI · Paper page
  111. Minichiello, E., Semerano, L. & Boissier, M. C. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: a systematic literature review. Joint Bone Spine 83, 625–630 (2016). · DOI
  112. Theander, L. et al. Severe extraarticular manifestations in a community-based cohort of patients with rheumatoid arthritis: risk factors and incidence in relation to treatment with tumor necrosis factor inhibitors. J. Rheumatol 44, 981–987 (2017). · doi:10.3899/jrheum.161103
  113. Radner, H., Neogi, T., Smolen, J. S. & Aletaha, D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 73, 114–123 (2014). · DOI · Paper page
  114. Hazlewood, G. et al. Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. J. Rheumatol. Suppl. 87, 54–58 (2011). · doi:10.3899/jrheum.101076
  115. Kurko, J. et al. Genetics of rheumatoid arthritis — a comprehensive review. Clin. Rev. Allergy Immunol. 45, 170–179 (2013). · DOI · Paper page
  116. Aletaha, D. & Smolen, J. S. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 63, 3702–3711 (2011). · DOI
  117. Gormley, G. J. et al. Can diagnostic triage by general practitioners or rheumatology nurses improve the positive predictive value of referrals to early arthritis clinics? Rheumatology 42, 763–768 (2003). · doi:10.1093/rheumatology/keg213
  118. Villeneuve, E. et al. A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Ann. Rheum. Dis. 72, 13–22 (2013). · DOI
  119. de Rooy, D. P., van der Linden, M. P., Knevel, R., Huizinga, T. W. & van der Helm-van Mil, A. H. Predicting arthritis outcomes — what can be learned from the Leiden Early Arthritis Clinic? Rheumatology 50, 93–100 (2011). · DOI · Paper page
  120. van der Helm- van Mil, A. H. et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 56, 433–440 (2007). · doi:10.1002/art.22380
  121. van Aken, J. et al. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann. Rheum. Dis. 73, 396–400 (2014). · DOI
  122. Weinblatt, M. E. Efficacy of methotrexate in rheumatoid arthritis. Br. J. Rheumatol 34 (Suppl. 2), 43–48 (1995). · doi:10.1093/rheumatology/xxxiv.suppl_2.43
  123. Visser, K. & van der Heijde, D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 68, 1094–1099 (2009). · DOI · Paper page
  124. van Ede, A. E. et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 44, 1515–1524 (2001). This study changed the approach to methotrexate therapy, showing that folate substitution does not reduce the efficacy but highly improves the tolerability of methotrexate, thus allowing optimal dosing of the drug. · DOI · Paper page
  125. Felson, D. T. et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727–735 (1995). · DOI · Paper page
  126. van der Heijde, D. M. et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann. Rheum. Dis. 51, 177–181 (1992). This article presents the first definition of a continuous measure for disease activity; its derivative, DAS28, became more widely used because it is less time-consuming to evaluate and further simplifications of composite measures were developed with CDAI and SDAI. · DOI · Paper page
  127. Smolen, J. S. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42, 244–257 (2003). · DOI · Paper page
  128. van der Heide, A. et al. The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann. Intern. Med. 124, 699–707 (1996). This is one of the first studies to reveal the importance of the early institution of DMARD therapy and thus the inappropriateness of the pyramid approach, although patients still had relatively long-standing disease. · DOI · Paper page
  129. Huizinga, W. J., Machold, K. P., Breedveld, F. C., Lipsky, P. E. & Smolen, J. S. Criteria for early rheumatoid arthritis: From Bayes’ law revisited to new thoughts on pathogenesis. (Conference summary). Arthritis Rheum. 46, 1155–1159 (2002). · DOI
  130. Nell, V. et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43, 906–914 (2004). · DOI · Paper page
  131. McCarty, D. J. Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J. Rheumatol 17, 1117–1118 (1990).
  132. Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263–269 (2004). · DOI · Paper page
  133. Aletaha, D. et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 52, 2625–2636 (2005). · DOI · Paper page
  134. Felson, D. T. et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70, 404–413 (2011). This paper provides a new definition for remission that is sufficiently stringent to be associated with lack of considerable residual disease activity, functional impairment and progression of damage. · DOI · Paper page
  135. Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3–15 (2016). This study defines the pathways to optimizing disease control in RA on the basis of available evidence and consensus finding, · DOI · Paper page
  136. Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552–1563 (1998). · DOI
  137. Mierau, M. et al. Assessing remission in clinical practice. Rheumatology 46, 975–979 (2007). · DOI · Paper page
  138. Verstappen, S. M. M. et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66, 1443–1449 (2007). · DOI · Paper page
  139. Klarenbeek, N. B. et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann. Rheum. Dis. 70, 1039–1046 (2011). · DOI · Paper page
  140. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76, 960–977 (2017). · DOI · Paper page
  141. Singh, J. A. et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 68, 1–25 (2016). · DOI · Paper page
  142. Lau, C. S. et al. APLAR rheumatoid arthritis treatment recommendations. Int. J. Rheum. Dis. 18, 685–713 (2015). · DOI
  143. Smolen, J. S., Aletaha, D., Grisar, J. C., Stamm, T. A. & Sharp, J. T. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann. Rheum. Dis. 69, 1058–1064 (2010). · DOI
  144. Aletaha, D., Smolen, J. & Ward, M. M. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 54, 2784–2792 (2006). · DOI · Paper page
  145. Aletaha, D., Alasti, F. & Smolen, J. S. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann. Rheum. Dis.https://doi.org/10.1136/annrheumdis-2015-208324 (2015). · DOI
  146. Haraoui, B. et al. Treating rheumatoid arthritis to target: a Canadian physician survey. J. Rheumatol. 39, 949–953 (2012). · doi:10.3899/jrheum.111134
  147. Pascual-Ramos, V., Contreras-Yanez, I., Villa, A. R., Cabiedes, J. & Rull-Gabayet, M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res. Ther. 11, R26 (2009). · DOI
  148. Schoenthaler, A. M., Schwartz, B. S., Wood, C. & Stewart, W. F. Patient and physician factors associated with adherence to diabetes medications. Diabetes Educ. 38, 397–408 (2012). · DOI
  149. Kuusalo, L. et al. Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. Scand. J. Rheumatol 44, 449–455 (2015). · DOI
  150. Solomon, D. H. et al. Implementation of treat to target in rheumatoid arthritis through a learning collaborative: results of the TRACTION trial. Arthritis Rheumatol. (in press).
  151. Smolen, J. S. & Aletaha, D. Forget personalised medicine and focus on abating disease activity. Ann. Rheum. Dis. 72, 3–6 (2013). · DOI
  152. Van der Heijde, D. M.F. M., van't Hof, M., van Riel, P. L. & van de Putte, L. B. A. Development of a disease activity score based on judgement in clinical practice by rheumatologists. J. Rheumatol 20, 579–581 (1993).
  153. Prevoo, M. L. L., van't Hof, M. A., Kuper, H. H., van de Putte, L. B. A. & van Riel, P. L.C. M. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44–48 (1995). · DOI · Paper page
  154. Bakker, M. F., Jacobs, J. W., Verstappen, S. M. & Bijlsma, J. W. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann. Rheum. Dis. 66 (Suppl. 3), iii56–iii60 (2007). · doi:10.1136/ard.2007.078360
  155. Smolen, J. S. & Aletaha, D. The assessment of disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 28 (Suppl. 59), S18–S27 (2010).
  156. Smolen, J. S. et al. Brief Report: Remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria. Arthritis Rheumatol. 69, 728–734 (2017). · DOI
  157. Smolen, J. S. & Aletaha, D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 63, 43–52 (2011). · DOI · Paper page
  158. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516–1523 (2008). · DOI · Paper page
  159. Schoels, M., Alasti, F., Smolen, J. S. & Aletaha, D. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res. Ther. 19, 155 (2017). · DOI
  160. Studenic, P., Smolen, J. S. & Aletaha, D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann. Rheum. Dis. 71, 1702–1705 (2012). · DOI
  161. Aletaha, D., Martinez-Avila, J., Kvien, T. K. & Smolen, J. S. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann. Rheum. Dis. 71, 1190–1196 (2012). · DOI
  162. Dorner, T. et al. The changing landscape of biosimilars in rheumatology. Ann. Rheum. Dis. 75, 974–982 (2016). · DOI · Paper page
  163. Schneider, C. K. Biosimilars in rheumatology: the wind of change. Ann. Rheum. Dis. 72, 315–318 (2013). · doi:10.1136/annrheumdis-2012-202941
  164. van der Goes, M. C. et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann. Rheum. Dis. 69, 1913–1919 (2010). · DOI · Paper page
  165. Verschueren, P. et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann. Rheum. Dis. 74, 27–34 (2015). · DOI
  166. de Jong, P. H. et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann. Rheum. Dis. 73, 1331–1339 (2014). · DOI
  167. Nam, J. L. et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann. Rheum. Dis. 73, 75–85 (2014). This is an important study showing that methotrexate plus glucocorticoids is not inferior to methotrexate plus anti-TNF in early RA, thus refuting the use of biological agents before methotrexate. · DOI
  168. LaRochelle, G. E. Jr, LaRochelle, A. G., Ratner, R. E. & Borenstein, D. G. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am. J. Med. 95, 258–264 (1993). · DOI · Paper page
  169. Pincus, T., Sokka, T., Castrejon, I. & Cutolo, M. Decline of mean initial prednisone dosage from 3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res. 65, 729–736 (2013). · DOI
  170. Smolen, J. S. et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum. 54, 702–710 (2006). · DOI · Paper page
  171. Kiely, P., Walsh, D., Williams, R. & Young, A. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity—the early RA network (ERAN). Rheumatology 50, 926–931 (2011). · DOI
  172. van der Lubbe, P. A., Dijkmans, B. S., Markusse, H., Nassander, U. & Breedveld, F. C. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis [abstract]. Arthritis Rheum. 38, 1097–1106 (1995). · DOI · Paper page
  173. Bonelli, M. et al. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum. 65, 599–607 (2013). · DOI
  174. Buch, M. H. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 909–920 (2011). · DOI · Paper page
  175. Nam, J. L. et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 76, 1113–1136 (2017). · doi:10.1136/annrheumdis-2016-210713
  176. Chatzidionysiou, K. et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 76, 1102–1107 (2017). · DOI · Paper page
  177. Fleischmann, R. et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 69, 506–517 (2017). · DOI · Paper page
  178. Fleischmann, R. et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 390, 457–468 (2017). · DOI · Paper page
  179. Weinblatt, M. E. et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 65, 28–38 (2013). · DOI · Paper page
  180. Porter, D. et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 388, 239–247 (2016). · DOI
  181. Smolen, J. S. et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 388, 2763–2774 (2016). · DOI · Paper page
  182. Taylor, P. C. et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N. Engl. J. Med. 376, 652–662 (2017). This is the first study to show any drug being superior to an anti-TNF in RA, here using baricitinib, an oral (small-molecule) DMARD that inhibits JNK1 and JNK2 (to learn more about the clinical implications of these data, more studies are needed). · DOI · Paper page
  183. Smolen, J. S. et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 383, 321–332 (2014). · DOI · Paper page
  184. Kavanaugh, A. et al. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Ann. Rheum. Dis.https://doi.org/10.1136/annrheumdis-2017-211871 (2017). · doi:10.1136/annrheumdis-2017-211871
  185. Kavanaugh, A. et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann. Rheum. Dis. 72, 64–71 (2013). · DOI
  186. Quinn, M. A. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52, 27–35 (2005). · DOI · Paper page
  187. Stamm, T. et al. Induction of sustained remission in ealry inflammatory arthritis with the combination of infliximab plus methotrexate, methotrexate alone or placebo: the DINORA trial [abstract]. Ann. Rheum. Dis. 76 (Suppl. 2), 560 (2017). · doi:10.1136/annrheumdis-2017-eular.3743
  188. Emery, P. et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann. Rheum. Dis. 74, 979–984 (2015). · DOI
  189. Holloway, K. & van Dijk, L. The World Medicines Situation 2011, Rational Use of Medicines 3rd edn (World Health Organzization, Geneva, 2011).
  190. Jorgensen, K. K. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389, 2304–2316 (2017). · DOI · Paper page
  191. Kay, J. et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann. Rheum. Dis.https://doi.org/10.1136/annrheumdis-2017-211937 (2017). · DOI · Paper page
  192. Scheiman, J. M. NSAID-induced gastrointestinal injury: a focused update for clinicians. J. Clin. Gastroenterol. 50, 5–10 (2016). · DOI
  193. Nissen, S. E. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 375, 2519–2529 (2016). · DOI · Paper page
  194. Strehl, C. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann. Rheum. Dis. 75, 952–957 (2016). · DOI · Paper page
  195. Burmester, G. R. et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann. Rheum. Dis. 76, 414–417 (2017). · DOI
  196. Strangfeld, A. et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res. Ther. 12, R5 (2010). · DOI · Paper page
  197. Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J. & Lacerda, A. P. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann. Rheum. Dis. 72, 517–524 (2013). · DOI · Paper page
  198. Strangfeld, A. et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann. Rheum. Dis. 76, 504–510 (2017). · DOI · Paper page
  199. Molloy, E. S., Calabrese, C. M. & Calabrese, L. H. The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management. Rheum. Dis. Clin. North Am. 43, 95–109 (2017). · doi:10.1016/j.rdc.2016.09.009
  200. Winthrop, K. L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat. Rev. Rheumatol 13, 234–243 (2017). · DOI · Paper page

200 of 243 shown

Cited by

See all 2,445

Metadata

Authors
Smolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., & Yamamoto, K.
Venue
Nature Reviews Disease Primers
Publisher
Springer Science and Business Media LLC
Published
2018-02-08
Volume
4
Issue
1
Pages
18001-18001
ISSN
2056-676X (ISSN-L)
DOI
10.1038/nrdp.2018.1
OpenAlex
W4211054359
Cited by
2,445
References
16
FWCI
35.27
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rheumatoid arthritis. https://app.cochat.ai/papers/10.1038/nrdp.2018.1
The paper
Smolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., & Yamamoto, K. (2018). Rheumatoid arthritis. Nature Reviews Disease Primers. https://doi.org/10.1038/nrdp.2018.1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.